← back to search

Shuichi Kaneko

Kanazawa University · JP
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis C virus research, Axon Guidance and Neuronal Signaling, Liver Disease Diagnosis and Treatment, and Hepatitis B Virus Studies.
h-index
51
citations
10,990
works
369
NIH funding
primary concept
Medicine
email

Recent publications

Systematic evaluation of long- and short-read RNA-seq for human peripheral blood.
2026cited by 0position: contributordoi
Author Correction: Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.
2026cited by 0position: contributordoi
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
ESMO Open 2025cited by 6position: middledoi
Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.
2024cited by 4position: contributordoi
EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma.
2023cited by 3position: contributordoi
Data from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S7 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
TABLE 1B from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S6 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S9 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 2 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Fig. S2 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
TABLE 1B from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Fig. S4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
FIGURE 4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S2 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Fig. S1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Fig. S3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S8 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
TABLE 2 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Table S3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi
Supplementary Fig. S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 59 papers (2020–2026)Taro Yamashita · Kanazawa University54 papers (2020–2026)Yohei Miyagi · Kanagawa Cancer Center51 papers (2023–2023)Takeshi Terashima · Elsevier, Inc.51 papers (2023–2023)Shinya Sato · Tokuyama (Japan)51 papers (2023–2023)Motoharu Seiki · Kanazawa University51 papers (2023–2023)Naohiko Koshikawa · Tokyo Institute of Technology51 papers (2023–2023)Toru Yoshimura · Abbott (Japan)51 papers (2023–2023)Makoto Ueno · Wakayama Medical University51 papers (2023–2023)Soichiro Morinaga · Kanagawa Cancer Center51 papers (2023–2023)Masatoshi Nakagawa · Abbott (Japan)51 papers (2023–2023)Eisaku Yoshida · University of Tsukuba51 papers (2023–2023)Yukinari Kato · Japan Agency for Medical Research and Development3 papers (2020–2026)Mami Yasukawa · 3 papers (2020–2026)Kenkichi Masutomi · SpringerNature3 papers (2020–2026)Toshihide Ueno · Shikoku Cancer Center2 papers (2024–2026)Hiroyuki Mano · National Cancer Research Institute2 papers (2024–2026) · 2 papers (2024–2026)Masahiko Watanabe · SpringerNature2 papers (2024–2026)Noriko Saitoh · The Cancer Institute Hospital2 papers (2024–2026)